MacroGenics scores first FDA approval with breast cancer med Margenza in third-line patients
In the sustainably hot oncology field, breast cancer has attracted some of the biggest players on the market, including blockbuster meds from Roche and Merck. Now, a new player has taken the field after the FDA gave a thumbs-up to newcomer MacroGenics and its HER2 expressing tumor fighter.
MacroGenics $MGNX scored its first FDA approval Wednesday for Margenza (margetuximab-cmkb) to treat metastatic HER2-positive breast cancer patients who have already received two or more prior HER2 regimens, including at least one in the metastatic setting, the Maryland biotech said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.